CRASH-2 - Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage

Harvard | Vancouver

CRASH-2 Collaborators. 2010. CRASH-2 - Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage. [Online]. London School of Hygiene & Tropical Medicine, London, United Kingdom. Available from: 10.17037/DATA.10 https://ctu-app.lshtm.ac.uk/freebird/index.php/available-trials/

Export Citation

Sharing

Description

A large randomised placebo controlled trial among trauma patients with or at risk of significant haemorrhage, of the effects of antifibrinolytic treatment on death and transfusion requirement. CRASH-2 is a randomised, controlled, double-blind trial undertaken in 274 hospitals in 40 countries. A total of 20211 adult trauma patients, with, or at risk of, significant bleeding (haemorrhage) were randomly assigned within 8 hours of injury to either tranexamic acid (TXA) or matching placebo. The primary outcome was death in hospital within four weeks of injury and was described with the following categories: bleeding, vascular occlusion (myocardial infarction, stroke and pulmonary embolism), multiorgan failure, head injury, and other.

Completed Date: 2010
Data capture method:
Mode of data capture
Field observation
Data Creators(s): CRASH-2 Collaborators
LSHTM Faculty/Department: Faculty of Epidemiology and Population Health > Dept of Population Health (2012- ) > Dept of Nutrition and Public Health Interventions Research (2003-2012)
Participating Institutions: London School of Hygiene & Tropical Medicine, London, United Kingdom

Files

Data
Documentation / Metadata

Related resources

LSHTM Open Access publications:

Resources

Actions

Edit Item Edit Item (admin only)